In the landscape of cancer research, abnormal epigenetic modifications emerge as crucial indicators, offering valuable insights into potential therapeutic avenues; that’s why proteins responsible for protein modification present opportunities for advancing cancer therapies. Among these proteins, SMYD2, a protein lysine methyltransferase, stands out as a significant player abundantly present in certain cancer types.
A recent French-American study has spotlighted SMYD2’s pivotal role in driving metastasis in breast cancers resistant to conventional treatments. In vitro experiments underscore the indispensability of SMYD2 for the development, migration, and invasion of cancer cells into surrounding tissues.
We at Lifency stay tuned and share information on medical progress, supporting scientists in their communication and knowledge sharing efforts.
Sources:
Zheng, Q., Zhang, W., & Rao, G. (2022). Protein lysine methyltransferase SMYD2 : a promising small molecule target for cancer therapy. Journal of Medicinal Chemistry, 65(15), 10119‑10132. https://doi.org/10.1021/acs.jmedchem.2c00325